Omega Fund Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-275,513
| Closed | -$510K | – | 14 |
|
|
2023
Q1 | $510K | Hold |
275,513
| – | – | 0.33% | 13 |
|
|
2022
Q4 | $306K | Hold |
275,513
| – | – | 0.1% | 15 |
|
|
2022
Q3 | $645K | Hold |
275,513
| – | – | 0.24% | 17 |
|
|
2022
Q2 | $835K | Hold |
275,513
| – | – | 0.27% | 20 |
|
|
2022
Q1 | $1.87M | Hold |
275,513
| – | – | 0.38% | 21 |
|
|
2021
Q4 | $2.3M | Hold |
275,513
| – | – | 0.33% | 21 |
|
|
2021
Q3 | $2.05M | Hold |
275,513
| – | – | 0.23% | 23 |
|
|
2021
Q2 | $1.87M | Hold |
275,513
| – | – | 0.21% | 23 |
|
|
2021
Q1 | $2.83M | Sell |
275,513
-59,452
| -18% | -$651K | 0.27% | 22 |
|
|
2020
Q4 | $2.35M | Hold |
334,965
| – | – | 0.35% | 17 |
|
|
2020
Q3 | $2.73M | Sell |
334,965
-195,000
| -37% | -$1.21M | 0.74% | 13 |
|
|
2020
Q2 | $3.66M | Hold |
529,965
| – | – | 1% | 13 |
|
|
2020
Q1 | $2.52M | Hold |
529,965
| – | – | 1.04% | 14 |
|
|
2019
Q4 | $4.63M | Hold |
529,965
| – | – | 1.47% | 12 |
|
|
2019
Q3 | $1.76M | Hold |
529,965
| – | – | 0.54% | 14 |
|
|
2019
Q2 | $2.62M | Hold |
529,965
| – | – | 0.67% | 13 |
|
|
2019
Q1 | $3.29M | Hold |
529,965
| – | – | 1.05% | 10 |
|
|
2018
Q4 | $1.79M | Hold |
529,965
| – | – | 1.32% | 12 |
|
|
2018
Q3 | $3.44M | Hold |
529,965
| – | – | 1.63% | 11 |
|
|
2018
Q2 | $4.06M | Hold |
529,965
| – | – | 3% | 10 |
|
|
2018
Q1 | $11.8M | Sell |
529,965
-49,685
| -9% | -$1.1M | 11.64% | 4 |
|
|
2017
Q4 | $7.39M | Hold |
579,650
| – | – | 5.34% | 5 |
|
|
2017
Q3 | $9.03M | Hold |
579,650
| – | – | 5.11% | 5 |
|
|
2017
Q2 | $8.13M | Hold |
579,650
| – | – | 5.07% | 5 |
|
|
2017
Q1 | $12.7M | Buy |
+579,650
| New | +$12.3M | 8.29% | 6 |
|
Other funds holding JNCE
Omega Fund Management's JNCE Position: Q2 2023 in Review
Omega Fund Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 275,513 shares — an estimated $510K sold.
Omega Fund Management first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $12.7M in Q1 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Omega Fund Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Omega Fund Management sold 275,513 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $510K.
- Omega Fund Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Omega Fund Management's Jounce Therapeutics, Inc. Common Stock position peaked at $12.7M in Q1 2017.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Omega Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.